[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  $orkas Oruka Therapeutics, Inc. (ORKA) sees positive developments as the FDA clears its IND application for Phase 2a trial of ORKA-001. Analysts are reiterating Buy ratings with price targets reflecting the positive developments. ### About $orkas Oruka Therapeutics, Inc. (ORKA) is a company focused on therapeutics. ### Engagements: XX [#](/topic/$orkas/interactions) ---  [Engagements 24-Hour Chart Data](/topic/$orkas/time-series/interactions.tsv) **Current Value**: XX **Daily Average**: XXX **1-Year High**: XXXXX on 2025-07-23 **1-Year Low**: X on 2025-07-06 | Social Network | X | | -------------- | - | | Engagements | XX | ### Mentions: X [#](/topic/$orkas/posts_active) ---  [Mentions 24-Hour Chart Data](/topic/$orkas/time-series/posts_active.tsv) **Current Value**: X **Daily Average**: X **1-Year High**: X on 2025-07-21 **1-Year Low**: X on 2025-05-22 | Social Network | X | | -------------- | - | | Mentions | X | ### Creators: X [#](/topic/$orkas/contributors_active) ---  [Creators 24-Hour Chart Data](/topic/$orkas/time-series/contributors_active.tsv) X unique social accounts have posts mentioning $orkas in the last XX hours which is no change from in the previous XX hours **Daily Average**: X **1-Year High**: X on 2025-05-22 **1-Year Low**: X on 2025-05-22 The most influential creators that mention $orkas in the last XX hours | Creator | Rank | Followers | Posts | Engagements | | ------- | ---- | --------- | ----- | ----------- | | [@Quantumup1](/creator/twitter/Quantumup1) | X | XXXXX | X | XXX | [View More](/list/creators/$orkas/100) **Top assets mentioned** In the posts about $orkas in the last XX hours [Johnson & Johnson (JNJ)](/topic/$jnj) [Oruka Therapeutics, Inc. Common Stock (ORKA)](/topic/$orka) [AbbVie Inc (ABBV)](/topic/$abbv) **Top topics mentioned** In the posts about $orkas in the last XX hours [$ucbjy](/topic/$ucbjy), [$jnj](/topic/$jnj), [$orka](/topic/$orka), [$abbv](/topic/$abbv), [hc](/topic/hc) ### Top Social Posts [#](/topic/$orkas/posts) --- Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized double-blind placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately XX patients randomized 3:1 to receive ORKA-001 or matching placebo. The" [@Quantumup1](/creator/x/Quantumup1) on [X](/post/tweet/1948085842020590074) 2025-07-23 18:20:33 UTC 3529 followers, 1203 engagements "Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt. $ABBV $PTGX $JNJ #EADV25 $UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating" [@Quantumup1](/creator/x/Quantumup1) on [X](/post/tweet/1947283589118198123) 2025-07-21 13:12:41 UTC 3530 followers, 4206 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Oruka Therapeutics, Inc. (ORKA) sees positive developments as the FDA clears its IND application for Phase 2a trial of ORKA-001. Analysts are reiterating Buy ratings with price targets reflecting the positive developments.
Oruka Therapeutics, Inc. (ORKA) is a company focused on therapeutics.
Engagements 24-Hour Chart Data
Current Value: XX
Daily Average: XXX
1-Year High: XXXXX on 2025-07-23
1-Year Low: X on 2025-07-06
Social Network | X |
---|---|
Engagements | XX |
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-07-21
1-Year Low: X on 2025-05-22
Social Network | X |
---|---|
Mentions | X |
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $orkas in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1-Year High: X on 2025-05-22
1-Year Low: X on 2025-05-22
The most influential creators that mention $orkas in the last XX hours
Creator | Rank | Followers | Posts | Engagements |
---|---|---|---|---|
@Quantumup1 | X | XXXXX | X | XXX |
Top assets mentioned In the posts about $orkas in the last XX hours
Johnson & Johnson (JNJ) Oruka Therapeutics, Inc. Common Stock (ORKA) AbbVie Inc (ABBV)
Top topics mentioned In the posts about $orkas in the last XX hours
$ucbjy, $jnj, $orka, $abbv, hc
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized double-blind placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately XX patients randomized 3:1 to receive ORKA-001 or matching placebo. The"
@Quantumup1 on X 2025-07-23 18:20:33 UTC 3529 followers, 1203 engagements
"Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt. $ABBV $PTGX $JNJ #EADV25 $UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating"
@Quantumup1 on X 2025-07-21 13:12:41 UTC 3530 followers, 4206 engagements
/topic/$orkas